We are catalyzing
innovation to accelerate
a cure for FSHD
Our purpose is to solve FSHD by December 31, 2027 with a focus on all forms of this rare neuromuscular disease. We will do this by removing barriers and accelerating development of novel therapies for FSHD.
Who We Are
Driving Innovation Toward
a Cure for FSHD
SOLVE FSHD is a venture philanthropic organization founded on the generous commitment of $100M USD from the Wilson family. We are part of a larger global FSHD community that has brought us to a place and time where cures for FSHD are possible. As a mission-driven organization, our unique approach is to be a catalyst, making strategic investments through partners in leading academic, biotech and biopharmaceutical organizations.
We will work with our partners and advisors in the life sciences community to develop a pipeline of new therapies and a cure by December 31, 2027. Once we have a SOLVE for FSHD we will continue to support the ongoing needs of this global community.
Funded to Date
We’re focused on funding research and clinical trials, partnering with academics and biotech companies.
What is FSHD?
Facioscapulohumeral muscular dystrophy
Facioscapulohumeral muscular dystrophy (FSHD) is a type of muscular dystrophy in which there is progressive muscle degeneration and muscle weakness. There is currently no treatment or cure.
Find Support
Resources for People With FSHD
Explore a network of organizations providing information, guidance, advocacy, direct support, and access to clinical trials for potential new therapies.